# Mendus

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/mendus).

## Overview

Mendus AB is a Swedish clinical-stage biopharmaceutical company focused on developing immunotherapies for myeloid blood cancers. Its lead asset, vididencel, is being developed in multiple leukemia settings through the company’s subsidiaries and research collaborations, with operations centered in Stockholm and R&D activities in Leiden and Australia.

## Products & services

• Vididencel immunotherapy platform for myeloid cancers
• DIVA trial program in acute myeloid leukemia (AML)
• VITAL-CML trial program in chronic myeloid leukemia (CML)
• Clinical development and translational research partnerships

- **Lead immunotherapy candidate** (100%) — Vididencel-based therapeutic development for myeloid malignancies.

- Vididencel immunotherapy platform for myeloid cancers
- DIVA trial program in acute myeloid leukemia (AML)
- VITAL-CML trial program in chronic myeloid leukemia (CML)
- Clinical development and translational research partnerships

## Customers

Mendus does not sell a commercial product base in the traditional sense; its primary counterparties are clinical investigators, research institutions, and potential licensing or collaboration partners. The company’s programs are aimed at patients with AML and CML, while future value creation depends on partners that can support development, commercialization, or regional execution.

- **Clinical trial investigators and sites** (primary) — Hospitals and trial centers that enroll patients into vididencel studies in AML and CML.
- **Research collaborators** (secondary) — Institutes such as ONJCRI that support trial execution, biomarker work, and clinical research.
- **Licensing and collaboration partners** (primary) — Biopharma partners that may fund, co-develop, or commercialize the asset in selected territories or indications.
- **Future treating physicians and oncology centers** (emerging) — Specialist hematology-oncology centers that would use the therapy if it reaches commercialization.

- Clinical trial sites enrolling AML and CML patients
- Research institutes supporting translational and trial work
- Potential pharma partners for licensing or collaboration
- Future healthcare providers and treatment centers
- Investors funding clinical-stage development

## Geography

Mendus is headquartered in Stockholm, Sweden, with R&D offices in Leiden, the Netherlands, and an Australian subsidiary. Its business is international by nature because clinical development, regulatory approvals, and future partnering can span multiple countries, even though the company currently reports no product revenue.

- Head office in Stockholm, Sweden
- R&D office in Leiden, the Netherlands
- Australian subsidiary supports clinical development
- Clinical and regulatory activity is multinational
- No disclosed product revenue by country

## Strategy

Mendus is focused on advancing vididencel through parallel clinical paths in AML and CML to broaden the asset’s potential use cases. The company also relies on collaborations and licensing options to extend development capacity and create future commercialization pathways.

- **Advance vididencel in AML** (short-term) — AML is the core development area and a key proof point for the platform.
- **Start and expand CML development** (short-term) — A second indication can broaden the addressable market and de-risk the asset.
- **Pursue collaborations and licensing** (medium-term) — External partners can provide capital, expertise, and commercialization reach.

- Advance vididencel in AML and CML
- Run parallel clinical programs to broaden value creation
- Use research partnerships to support trial execution
- Preserve optionality for licensing or collaboration deals
- Secure funding to keep development programs moving

## Risks

Mendus is exposed to the high failure rate and long timelines typical of clinical-stage biotech, where trial outcomes and regulatory decisions can materially change the value of a program. The company also faces financing risk, dependence on intellectual property, and reliance on external partners and approval/reimbursement regimes for any future commercialization.

- **Insufficient financing** [critical] — The company states that available liquidity may not fund operations beyond the beginning of 2027.
- **Clinical development risk** [high] — Vididencel must show efficacy and safety in AML and CML trials before value can be realized.
- **Regulatory and reimbursement risk** [high] — Approval and reimbursement regimes can affect trial progression and future market access.
- **Intellectual property dependence** [high] — The asset’s commercial value depends on patent and know-how protection.

- Clinical trial failure could reduce or eliminate asset value
- Funding needs are critical before programs can reach later stages
- Dependence on IP protection and collaboration agreements
- Regulatory and reimbursement pathways may change over time
- Biotech development timelines are long and capital intensive

## Accounting

As a clinical-stage biotech with no product revenue, Mendus’ reported results are driven mainly by research and development, administrative costs, and non-cash items such as warrants and share-based remuneration. The company also uses IFRS fair value and acquisition accounting for group investments, while liquidity and going-concern judgments are especially important because they affect how investors interpret the sustainability of the business.

- **Going concern and liquidity assessment** — Affects valuation of the company and interpretation of the financial statements
- **Warrants and share-based remuneration** — Can distort period-to-period comparability of operating loss
- **Fair value of financial instruments** — Affects liabilities, trade payables, and financing-related disclosures
- **Acquisition accounting for subsidiaries** — Influences consolidation balances and equity presentation

- No revenue means expenses and cash burn dominate reported performance
- Warrants and share-based pay create non-cash P&L volatility
- Going-concern and liquidity judgments are material
- Acquisition method affects consolidation of subsidiaries
- Fair value and financial instrument estimates affect balance sheet items

---

*Last updated: 2026-08-11T04:04:54.170179+00:00*